BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210427
DTEND;VALUE=DATE:20210430
DTSTAMP:20260515T172354
CREATED:20210115T080512Z
LAST-MODIFIED:20210115T080512Z
UID:28488-1619481600-1619740799@www.pharmajournalist.com
SUMMARY:Interstitial Lung Disease Drug Development Summit
DESCRIPTION:Network with over 50 other industry pioneers including Ionis Pharmaceuticals\, Genentech\, Vicore and AnaMar to hear first-hand how the latest scientific research is innovating and upgrading ILD therapeutics at this trailblazing new meeting. \n \nThe 1st Interstitial Lung Disease Drug Development Summit is a ground-breaking new conference dedicated to helping you drive forward the development of effective therapies for chronic fibrosing ILDs and achieve success in anti-fibrotic drug development beyond IPF. \nVisit our website to download our event guide.
URL:https://www.pharmajournalist.com/event/interstitial-lung-disease-drug-development-summit/
LOCATION:Virtual Conference
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210427
DTEND;VALUE=DATE:20210430
DTSTAMP:20260515T172354
CREATED:20210118T174336Z
LAST-MODIFIED:20210118T174336Z
UID:28564-1619481600-1619740799@www.pharmajournalist.com
SUMMARY:3rd Neuroimmunology Drug Development Summit
DESCRIPTION:As diverse programs are advancing towards the clinic\, there is a dire need to tackle the many translational challenges neuro-immunologists are facing to develop clinically effective neuroimmunology targeted therapeutics. \n \nBuilding on the success of last year’s meeting\, the 3rd Neuroimmunology Drug Development Summit will uncover how leading companies in this emerging field are discovering immune-modulating targets and deploying immuno-neurology across clinical case studies. As we gather the best minds in this infant field we will put a spotlight on the latest key learnings across microglia\, astrocytes\, STING\, TREM2 and more to help pave the way to translating key technological and mechanistic insights towards the clinic. \nJoin this intimate\, industry led forum to not only learn from those pioneering the field\, but to network and build meaningful partnerships with 80+ neuroimmunology drug development experts. \nTo find out more and view the 2021 speaker line-up\, download the 2021 event guide.
URL:https://www.pharmajournalist.com/event/3rd-neuroimmunology-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210427
DTEND;VALUE=DATE:20210430
DTSTAMP:20260515T172354
CREATED:20210121T100547Z
LAST-MODIFIED:20210121T100547Z
UID:28587-1619481600-1619740799@www.pharmajournalist.com
SUMMARY:Mitochondria-Targeted Drug Development Digital Summit
DESCRIPTION:The Mitochondria-Targeted Drug Development Digital Summit is the only industry-led meeting focused on end-to-end mitochondria-targeting. Explore success stories from leading experts overcoming common challenges whilst exploring what’s next to help you accelerate your pipeline into the clinic. \nWith 20+ hours of content\, 2 interactive workshops and over 5 hours of networking with key industry leaders from Larimar Therapeutics\, Minovia Therapeutics\, Mitokinin and many more\, this comprehensive forum will completely focus on mitochondria-targeting drug development and the current challenges and opportunities in the field. \n \nMake this your 2021 must-attend meeting and network with 80+ senior CSOs\, CEOs\, research scientists\, academics and investors committed to targeting mitochondria to tackle challenges with Mitochondrial & Age-related Diseases. \nIn this focused summit\, you’ll learn from the field’s pioneers who’ll be sharing their experience in: \n\nExploring the role of mitochondrial dysfunction in age-related diseases & rare genetic mitochondrial diseases\nExamining early discovery and research findings\nEvaluating preclinical drug development and studies\nDiscovering the patient perspective to aid mitochondria-targeted drug development\nAssessing clinical development and showcasing current trials\nLessons learned from clinical trial design and how design can be improved to mitigate common challenges\nRealizing the use of gene therapy\, editing technology and innovation\n\nTo know more about Mitochondria-Targeted Drug Development Digital Summit please click here.
URL:https://www.pharmajournalist.com/event/mitochondria-targeted-drug-development-digital-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210428
DTEND;VALUE=DATE:20210430
DTSTAMP:20260515T172354
CREATED:20210122T095626Z
LAST-MODIFIED:20210122T095626Z
UID:28611-1619568000-1619740799@www.pharmajournalist.com
SUMMARY:SMi’s 4th Annual Pharmaceutical Microbiology East Coast Conference
DESCRIPTION:Sponsor: Microcoat \nChaired by Lynne Ensor\, Vice President\, RCS Head of Global Compliance\, Parexel \nExploring Agile Contamination Control Strategy \nBiologic products require diligent microbial control because of their complex and sometimes growth-promoting manufacturing processes\, and high-risk patient populations. The increase in complexity of pharmaceutical products\, rise in development of biologics and increasingly stringent regulations for biologics are some of the factors that are driving the growth of the pharmaceutical microbiology market for biopharmaceutical products. \n \nSMi Group invite all microbiologists to join the virtual conference to discuss Contamination Control Strategies\, Effective Environmental Monitoring\, and the newest schools of thought in personnel operation. Leaders in regulation and compliance will provide expert viewpoints on how to implement and interpret the regulation\, in addition\,  Annex 1 will be assessed and debated. \nThe industrial microbiology market is made up of equipment and systems. The equipment comprises the filtration pumps & systems\, microbial detection systems\, air monitoring systems\, incubators & culture apparatus\, etc. This equipment is used in series of microbiological tests by the industry\, where they play a vital role as they provide the ease in the testing procedure. In industrial microbiology test types\, microbial tests are carried out to study the total viable count of the specific organism present in a solution. \nThe Microbiological industry continues to swell and is set to reach a Record CAGR of 7.1% Rise in Growth by 2024. The Global Clinical Microbiology Market is expected to reach USD 4.95 billion by 2023. \nEvent Hashtag: #SMiPharmaMicroEC \nHighlights for 2021: \n\nEXPLORE the latest advancements in robust risk-based disinfection strategies for effective cleaning and microbe elimination\nINVESTIGATE the extensive and complex regulatory landscape alongside the regulators\nDELVE into recent case studies delivered by experts in microbial monitoring and contamination control programs\nATTAIN expert tuition at the post-conference workshops in new quality risk management tools for contamination control and the latest revisions in the USP\nVIRTUAL CONFERENCE benefits include: virtual exhibition booths packed with information\, networking features to discuss and share contact details with other attendees\, and virtual meetings and networking socials\n\n2 Interactive Pre-Conference Workshops on April 27\, 2021 \nWorkshop A: USP Microbiology 2021 – Keeping Up with Standards \nLed by: Donald Singer\, Microbiology Expert Committee Chair\, US Pharmacopoeia \nWorkshop B: Quality Risk Management Tools for Contamination Control \nLed by: Cheryl Essex\, Head of Microbiological Control for Biologics\, Sanofi and Jon Williams\, Global Proactive Risk Manager\, Sanofi \nView the full agenda: www.microbiologyeastcoast.com  \nWHO SHOULD ATTEND? \nSenior Microbiologist\, Lead Scientist\, Laboratory Manager\, QA Specialist\, Drug Substance External Manufacturer\, QC Scientists\, Heads of Quality\, Business Development Manager\, Pharmaceutical Microbiology Consultant\, Higher Pharmacopoeia Scientist\, Analytical Standards Specialist
URL:https://www.pharmajournalist.com/event/smis-4th-annual-pharmaceutical-microbiology-east-coast-conference/
LOCATION:Online Access Only
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210428
DTEND;VALUE=DATE:20210430
DTSTAMP:20260515T172354
CREATED:20210208T082114Z
LAST-MODIFIED:20210208T082114Z
UID:28846-1619568000-1619740799@www.pharmajournalist.com
SUMMARY:Triple Negative Breast Cancer Drug Development Digital Summit
DESCRIPTION:Improving the Safety\, Efficacy & Predictability of Monotherapy & Combinatorial Therapies to Fast-track the Discovery & Development of TNBC Treatments to Reach Patients in Need \nThis is the primary industry platform specifically dedicated to providing you insight into the latest developments of safe and efficacious blockbuster therapies to treat triple negative breast cancer. \nBreast cancer (BC) is the most common solid tumor in women\, with the triple negative subtype associated with poorer overall survival and a higher probability of cancer recurrence. \nGiven the large unmet clinical need in this oncology indication and aligned with recent clinical trial progress\, the Triple Negative Breast Cancer (TNBC) Drug Development Digital Summit has been created to provide insight into industry- and academic-led clinical programs developing immune checkpoint\, DDR inhibitor\, ADC and other novel agents. \nThis is the industry’s definitive conference specifically dedicated to advancing the development of both monotherapy and combinatorial therapies to improve the current standard of care for patients with TNBC. \nJoin leading experts from CytoDyn\, Zenith Epigenetics\, Oncorus\, University of Pittsburgh and more who are identifying specific molecular targets\, such as immune checkpoint modulators\, intra-nuclear targets\, intracellular targets\, and cell surface targets\, to limit the progression and metastasis of this invasive tumor and improve patient outcomes. \nWhether you are developing a TROP2-ADC\, a PARP inhibitor\, a viral immunotherapy or a cancer vaccine for treating TNBC\, this dedicated digital meeting is your opportunity to discuss novel\, cutting edge targeted therapies in TNBC and get a full picture of the clinical landscape. \nTo know more about Triple Negative Breast Cancer Drug Development Digital Summit please click here.
URL:https://www.pharmajournalist.com/event/triple-negative-breast-cancer-drug-development-digital-summit/
LOCATION:Virtual/Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210428
DTEND;VALUE=DATE:20210430
DTSTAMP:20260515T172354
CREATED:20210222T084218Z
LAST-MODIFIED:20210222T084218Z
UID:29072-1619568000-1619740799@www.pharmajournalist.com
SUMMARY:The 4th Global NASH Congress
DESCRIPTION:The Global NASH Congress programme creates a collaborative environment in which you can create enduring relationships across the full range of disciplines engaged in NASH research & drug discovery and development. \n \n\nLearn how to integrate NAFLD Screening into secondary and tertiary care\nDiscover the regulatory pathways for approval of biomarkers in NAFLD patients\nReview the current and potential biomarkers for staging\nInvestigate if targeting fructose metabolism offers a NAFLD/NASH therapy\nHear how belapectin\, a galectin-3 (Gal-3) inhibitor\, is in development for the prevention of oesophagal varices in patients with NASH cirrhosis\nExplore the Epidemiology of NAFLD\n\nTo know more about The 4th Global NASH Congress please click here.
URL:https://www.pharmajournalist.com/event/the-4th-global-nash-congress/
LOCATION:Online & on-demand
ORGANIZER;CN="Global Engage":MAILTO:nnoakes@globalengage.co.uk
END:VEVENT
END:VCALENDAR